Contact Us

Management Team

Jon Burrows, Ph.D., President and Chief Executive Officer

Dr. Burrows brings extensive experience in development of clinical tissue assays and a deep understanding of cancer pathways and drug development. Prior to joining Expression Pathology he held management roles at Ventana Medical Systems (a member of the Roche group) in business development and R&D with responsibilities for managing companion diagnostic development collaborations with major biopharmas. Previous roles included research and management positions with Novartis, Chiron, Rigel and Sugen/Pharmacia.

 

 

Thomas G. Guiel, Chief Operating Officer, Executive Vice President

Mr. Guiel is an expert in operations and logistics with extensive experience in establishing and managing new business operations.  At Life Technologies (1985 – 2003), he was responsible for establishing distribution, manufacturing and quality systems for early-stage ventures in Brazil, Hong Kong, Japan, New Zealand, Scotland and throughout the US. Mr. Guiel led global teams in the development and implementation of high-throughput automation and the integration of complex and disparate IT systems.


David Krizman, Ph.D., Chief Scientific Officer and Co-founder

Dr. Krizman is a pioneer in applications of novel genomic/proteomic technologies to the analysis of cancer tissue. He received his Ph.D. from the University of Texas/M.D. Anderson Cancer Center. Prior to founding Expression Pathology in 2001, Dr. Krizman was an original staff member of the newly-created National Human Genome Research Institute in 1993. He then moved to a research staff position at the National Cancer Institute in 1996. During his tenure as Principal Investigator at the NCI, he co-founded and helped lead the Cancer Genome Anatomy Project. Dr. Krizman has served on numerous government committees, NIH study sections, and NCI advisory groups.  He has authored more than 60 peer-reviewed manuscripts, textbook chapters, and review articles on the subjects of cancer biology, human genetics, and proteomics. 

 

Marlene Darfler, Vice President Product Development and Co-founder

Ms. Darfler brings extensive experience developing research and diagnostic tissue analysis methods as a former senior research scientist at Invitrogen.

 

 

 

Linda A. Broenniman, Chief Financial Officer

Ms. Broenniman has a solid background as an executive in operations and financial management, primarily with emerging companies. She is an experienced entrepreneur, who founded and built a medical technology company as President/CEO. She has been CFO of a public company and her experience includes several M & A and capital transactions.